Back to Search Start Over

An isoform of the giant protein titin is a master regulator of human T lymphocyte trafficking.

Authors :
Toffali L
D'Ulivo B
Giagulli C
Montresor A
Zenaro E
Delledonne M
Rossato M
Iadarola B
Sbarbati A
Bernardi P
Angelini G
Rossi B
Lopez N
Linke WA
Unger A
Di Silvestre D
Benazzi L
De Palma A
Motta S
Constantin G
Mauri P
Laudanna C
Source :
Cell reports [Cell Rep] 2023 May 30; Vol. 42 (5), pp. 112516. Date of Electronic Publication: 2023 May 18.
Publication Year :
2023

Abstract

Response to multiple microenvironmental cues and resilience to mechanical stress are essential features of trafficking leukocytes. Here, we describe unexpected role of titin (TTN), the largest protein encoded by the human genome, in the regulation of mechanisms of lymphocyte trafficking. Human T and B lymphocytes express five TTN isoforms, exhibiting cell-specific expression, distinct localization to plasma membrane microdomains, and different distribution to cytosolic versus nuclear compartments. In T lymphocytes, the LTTN1 isoform governs the morphogenesis of plasma membrane microvilli independently of ERM protein phosphorylation status, thus allowing selectin-mediated capturing and rolling adhesions. Likewise, LTTN1 controls chemokine-triggered integrin activation. Accordingly, LTTN1 mediates rho and rap small GTPases activation, but not actin polymerization. In contrast, chemotaxis is facilitated by LTTN1 degradation. Finally, LTTN1 controls resilience to passive cell deformation and ensures T lymphocyte survival in the blood stream. LTTN1 is, thus, a critical and versatile housekeeping regulator of T lymphocyte trafficking.<br />Competing Interests: Declaration of interests The authors declare no competing interests.<br /> (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2211-1247
Volume :
42
Issue :
5
Database :
MEDLINE
Journal :
Cell reports
Publication Type :
Academic Journal
Accession number :
37204926
Full Text :
https://doi.org/10.1016/j.celrep.2023.112516